Business Context and Reporting Period
This Form 8-K filing by Progyny, Inc. (PGNY) reports a corporate governance event dated August 30, 2022. The Company, incorporated in Delaware and listed on the Nasdaq Global Select Market, announced an expansion of its Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
- Board Expansion: The Board size increased from nine (9) to ten (10) directors.
- New Appointment: Lloyd H. Dean was appointed as a Class I director, effective August 30, 2022, with a term expiring at the 2023 annual meeting.
- Committee Assignment: Mr. Dean was appointed to the Nominating and Corporate Governance Committee.
Management Commentary, Risks, and Unusual Items
Compensatory Arrangements:
- Cash Retainer: $40,000 annual cash retainer, payable quarterly in arrears.
- Initial Equity Grant: Option to purchase 44,000 shares of common stock. Vesting schedule: 25% on the first anniversary, with the remainder vesting in equal quarterly installments over the subsequent three years.
- Future Annual Grants: Eligibility for an annual option grant of 25,000 shares and 5,000 restricted stock units (RSUs), granted annually on October 24, vesting on the first anniversary.
Background: Mr. Dean previously served as CEO of CommonSpirit Health (2019–2022) and Dignity Health (2000–2019). He also serves on the boards of McDonald's Corporation and other entities.
Risks and Contingencies: The filing states there are no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K and no family relationships with other directors or officers. Mr. Dean entered into the Company's standard indemnity agreement.
Investor Verification Checklist
- Verify the impact of the new board composition on corporate governance strategy.
- Review the dilution impact of the initial 44,000 share option grant and future annual grants.
- Confirm the vesting conditions tied to Mr. Dean's continued service.
- Check for any subsequent filings regarding the 2023 annual meeting where Mr. Dean's term expires.